Stock Code: 600079 Stock Abbreviation: Renfu Pharmaceutical Announcement No.: 2022-057
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and bear individual and joint responsibility for the authenticity, accuracy and completeness of the content.
Important content reminder:
?Basic shareholding: As of the date of this announcement, Mr. Wang Xuehai, director of Renfu Pharmaceutical Group Co., Ltd. (hereinfollowing referred to as the “Company”), holds 5,515,346 shares of the company, accounting for 0.34% of the company’s total share capital, all of which are unrestricted tradable shares .
?Progress of the shareholding reduction plan by centralized bidding: For details of Mr. Wang Xuehai’s shareholding reduction plan, please refer to the announcement published by the company on the website of the Shanghai Stock Exchange on January 11, 2022; A total of 360,000 shares were reduced, accounting for 0.02% of the company’s total share capital.
1. The basic situation of the main body before the reduction of holdings through centralized bidding
Note: Shares obtained by non-public issuance include the conversion of capital reserve into shares, and shares obtained by other means are restricted stock incentive shares and capital reserve conversion shares.
There is no concerted action in the above-mentioned reduction subjects.
2. The implementation progress of the centralized bidding reduction plan
(1) The directors disclosed the progress of the implementation of the centralized bidding reduction plan for the following reasons:
Less than half of the time
(2) Whether the reduction of this shareholding is consistent with the plans and commitments previously disclosed by major shareholders or directors, supervisors and senior executives
(3) During the time period for the reduction of holdings, whether the listed company discloses major matters such as high-speed transfer or planning for mergers and acquisitions
(IV) The impact of this reduction on the company
This share reduction plan is a normal reduction of the company’s directors, and will not have a significant impact on the company’s governance structure, shareholding structure and future sustainable operations.
3. Risk reminders related to the centralized bidding reduction plan
(1) This share reduction plan is decided by the company’s director Mr. Wang Xuehai according to his own needs. During the reduction period, Mr. Wang Xuehai will choose whether to implement and how to implement the share reduction plan according to market conditions, the company’s stock price and other factors. Quantity and price are uncertain.
(2) Whether the implementation of the shareholding reduction plan will lead to the risk of changing the control of the listed company
(3) Mr. Wang Xuehai will strictly abide by the “Company Law”, “Securities Law”, “Several Regulations on Share Reduction by Shareholders of Listed Companies, Directors, Supervisors and Senior Management” and “Reduction of Shares by Shareholders, Directors, Supervisors and Senior Management of Listed Companies on the Shanghai Stock Exchange” Shares are reduced in accordance with the requirements of relevant laws, regulations and normative documents such as the Detailed Implementation Rules and the Shanghai Stock Exchange Listing Rules.
Special announcement.
Board of Directors of Renfu Pharmaceutical Group Co., Ltd.
May 7, 2022
<!–
–>
